Search PubMed⌕ Search

PubMed · 15497795

[Emphysema].

Abstract

The term emphysema refers both to abnormal enlargement and destruction of distal spaces of the lung. Diagnosis of emphysema is achieved by high resolution CT-scan of the thorax. Advanced forms of emphysema are associated with severe respiratory insufficiency. Isolated forms of emphysema may present as giant bullae with normal surrounding parenchyma. Diffuse panlobular emphysema is frequently associated with a genetic disease characterized by a severe deficit in alpha1-antitrypsin (AAT). Common forms of emphysema are observed in the distal lung of patients with COPD, or around fibrous and retractile lesions of the lung. Apart from the possible beneficial effect of augmentation therapy in case of severe deficit in AAT, there is no medical therapy currently active on the emphysematous process. Surgical approaches include bullaectomy which may be indicated in some cases of giant bullae, and lung transplantation and lung volume reduction surgery whose indications are both restricted to selected cases of advanced emphysema.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Michel Fournier. 2004-09-15. [Emphysema].. https://pubmed.ncbi.nlm.nih.gov/15497795/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

In HLH-94, the first prospective international treatment study for hemophagocytic lymphohistiocytosis (HLH), diagnosis was based on five criteria (fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, and hemophagocytosis). In HLH-2004 three additional criteria are introduced; low/absent NK-cell-activity, hyperferritinemia, and high-soluble interleukin-2-receptor levels. Altogether five of these eight criteria must be fulfilled, unless family history or molecular diagnosis is consistent with HLH. HLH-2004 chemo-immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy with methotrexate and corticosteroids. Subsequent hematopoietic stem cell transplantation (HSCT) is recommended for patients with familial disease or molecular diagnosis, and patients with severe and persistent, or reactivated, disease. In order to hopefully further improve diagnosis, therapy and biological understanding, participation in HLH studies is encouraged.

Diagnosis, Differential↗